ViraCor/IBT Laboratories merge
This article was originally published in The Gray Sheet
Privately-held providers of testing and clinical trial services agree to merge for undisclosed terms, creating a "new specialty diagnostics laboratory," they announce June 30. ViraCor Laboratories President John Martin, who will also serve as president of the new firm, said the merger "gives ViraCor and IBT the combined scientific know-how and national network not only to reach additional customers who could benefit from our current test menu, but also to expand our services." ViraCor, based in Lee's Summit, Mo., specializes in molecular diagnostic testing for infectious diseases. Lenexa, Ks.-based IBT focuses on immunology and allergy testing. Both companies will continue to operate their respective facilities
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.